Moderna (MRNA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.97
- Estimate
- -$2.06
- Surprise
- +4.3%
- Revenue (period 2026-06-30)
- $145.0M
- Score at report (before → after)
- 4.6 → 4.5/10
Revenue source: xbrl.
How the report landed
Moderna (MRNA) reported a narrower loss than forecast — diluted EPS of -$1.97 against the -$2.06 estimate (a 4.3% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Data Issue (4.6/10) to Sell at 4.5/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MRNA Sell at 3.9/10.
4 of the last 4 quarters beat the estimate; this quarter's +4.3% surprise compares with a +28.3% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-25.3% upside)
- Quality below floor (3.4 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 166.7), Material insider selling (4 sells, 0.02% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $144.65
- Price target
- $173.13
- Stop
- $133.89
- Upside to target
- +19.7%
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
MRNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $57.48B
- P/E (fwd)
- -32.2
- 52-week range
- $22.28–$176.66
- Off 52-week high
- 18.1%
- RSI (14)
- 49
- Volume vs avg
- 0.45×
- Score today
- 3.9/10